CAR-T Therapy Market Definition

Central Nervous System Drugs Market Definition

Pharmaceutical Drugs Market Definition

Oncology Drugs Market Definition

Dry Eye Medication Market Definition

The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders. The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the genito-urinary drugs industry in the historic period. Pharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In December 2019, GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA ® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Major companies in the genito-urinary drugs market include Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. North America was the largest region in the genito-urinary market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global genito-urinary drugs market is segmented - 1) By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, brain tumor, and other different cancer types. The main types of oncology drugs are lung cancer drugs, pancreatic cancer drugs, breast cancer drugs, prostate cancer drugs, ovarian cancer drugs, colorectal cancer drugs, gastric cancer drugs, kidney cancer drugs, brain tumor drugs, thyroid cancer drugs, skin cancer drugs, bladder cancer drugs, cervical cancer drugs, blood cancer drugs and others (kaposi sarcoma, aids-related lymphoma, anal cancer, bone cancer, retinoblastoma, testicular cancer, hepatocellular (liver) cancer, mouth cancer, neuroblastoma). Breast cancer drugs are used to target and destroy breast cancer cells. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global oncology drugs market size is expected to grow from $199.95 billion in 2021 to $223.21 billion in 2022 at a compound annual growth rate (CAGR) of 11.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oncology drugs market is expected to reach $540.60 billion in 2026 at a CAGR of 24.8%. The outbreak of the Coronavirus disease (COVID-19) has acted as a significant restraint on the oncology drugs market in 2020 as supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and spread globally including Western Europe, North America and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of lockdown and the outbreak had a negative impact on businesses throughout 2020 and into 2021. Pharmaceutical markets such as this one has been relatively unaffected however due to continued availability of drugs during government lock downs and inelasticity of demand. It is expected that the oncology market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy. Companies in the oncology drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major oncology drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For example, Johnson and Johnson has recently entered into an agreement with BenevolentAI, a UK-based start-up, to mine data for designing new oncology drugs. Companies in the oncology drug market are investing in targeted therapy, which has proven to be less toxic compared to traditional treatment options. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Companies in oncology market such as Pfizer, Novartis and Abbvie have understood the importance of this treatment method and are increasingly investing in it. According to a report by QuintilesIMS, 87% of the drugs currently in pipeline constitute of targeted therapy drugs. Major companies in the oncology drugs market include F. Hoffmann-La Roche Ltd, Novartis AG, Gilead Sciences Inc, Bayer AG, and Takeda Pharmaceticals. North America was the largest region in the oncology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period The regions covered in the oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oncology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global oncology drugs market is segmented - 1) By Type: Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The ophthalmology drugs market consists of sales of ophthalmology drugs and related services by entities (organizations, sole traders and partnerships) that produce ophthalmology drugs to treat eye related diseases. The ophthalmology drugs industry includes establishments that produce pharmaceutical drugs to treat glaucoma diseases, anti- inflammatory and tear stimulating drugs under dry eye medications drugs, and other drugs for treating retinal disorders and allergies. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax. The main types of ophthalmology drugs are antiglaucoma drugs, dry eye medication, and other ophthalmological drugs (retinal disorders, anti-infectives/allergy). Anti-glaucoma drugs are medications used to prevent or treat glaucoma, which is a disease in which the optic nerve is damaged, resulting in progressive, irreversible vision loss. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global ophthalmology drugs market size is expected to grow from $50.62 billion in 2021 to $56.07 billion in 2022 at a compound annual growth rate (CAGR) of 10.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The ophthalmology drugs market is expected to reach $127.15 billion in 2026 at a CAGR of 22.7%. The expected rise in eye laser surgeries will contribute to the ophthalmology drugs market. Ophthalmology research has proved a link between laser eye surgeries and the prevalence of dry eye disorders. In an eye laser procedure, cutting of some nerves in the cornea leads to reduction in corneal sensitivity, in response to which, eyes may not sense the need for lubrication, causing the body to produce fewer tears. Dry eye is a common side effect after laser vision correction surgeries. It is estimated that almost half of the patients that undergo a laser surgery experience some degree of dry eye condition following the procedure. The number of eye laser procedures rose to 720,000 a year in 2020. A rising number of people going for laser eye surgeries is expected to increase the demand for dry eye medications in the forecast period driving the ophthalmology drugs market. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes. For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies. The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA). It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the ophthalmology drugs market. Drug manufacturers are increasingly developing ophthalmic drugs with anti-inflammatory agents to ease patient treatment for dry eye syndrome. Anti-inflammatory drugs are widely used for the treatment of the inflammation produced by the dry eye syndrome, with the topical corticosteroid drops being the most common therapy. Corticosteroids can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye. However, prolonged usage of corticosteroids has seen to produce side effects that include risk of bacterial or fungal infection, elevated intraocular pressure and cataract formation. As a consequence, NSAIDs are increasingly being used as dry eye treatment instead of steroids to minimize the side effects. For instance, Aciex Therapeutics, a US-based pharmaceutical company, is developing NSAIDs which decrease ocular discomfort. Major companies in the ophthalmology drugs market include Regeneron Pharmaceuticals, Inc., Novartis AG, AbbVie, Santen Pharmaceutical Co., F. Hoffmann-La Roche Ltd., Bausch Health Companies Inc., Bayer AG, Sumitomo Chemical Co ltd, Mitsubishi Tanabe Pharma Corporation and Horizon Therapeutics plc. North America was the largest region in the ophthalmology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the ophthalmology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ophthalmology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global ophthalmology drugs market is segmented - 1) By Type: Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs